Parexel

Parexel

Focused on the development of innovative new therapies to improve the world’s health.

  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

-
*

N/A

-

$8.5b

Valuation: $8.5b

Buyout
Total Funding-

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2015
Revenues0000
EBITDA0000
Profit0000
EV0000
EV / revenue00.0x
EV / EBITDA00.0x
R&D budget0000

Source: Company filings or news article

More about Parexel
Made with AI
Edit

Parexel is a leading clinical research organization (CRO) that specializes in providing a full range of Phase I to IV clinical development services. The company operates in the pharmaceutical and biotechnology sectors, primarily serving clients who are developing new treatments and therapies. Parexel's business model revolves around offering end-to-end clinical trial management, regulatory consulting, and biostatistical analysis to ensure the efficient and effective development of new drugs. The company generates revenue through service contracts with pharmaceutical companies, biotech firms, and medical device manufacturers. Parexel is recognized for its expertise, quality, and reliability, having received multiple industry awards. The company is also committed to advancing gender partnership and leadership within its organization.

Keywords: clinical research, Phase I-IV trials, regulatory consulting, biostatistics, pharmaceutical, biotechnology, drug development, patient-centric, CRO, life sciences.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Parexel

Edit
Liquent
ACQUISITION by Parexel Dec 2012
ExecuPharm
ACQUISITION by Parexel Sep 2016
Health Advances
ACQUISITION by Parexel Jan 2016
Model Answers
ACQUISITION by Parexel Mar 2020